menu
    • menu
    [{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"MEN1309","moa":"CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Cell therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biotherapeutics \/ Kite","highestDevelopmentStatusID":"2","companyTruncated":"Oxford Biotherapeutics \/ Kite"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"MEN1309","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Balstilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Agenus","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Agenus"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"MEN1309","moa":"CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Immunogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"OBT227","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biotherapeutics \/ ImmunoGen","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Biotherapeutics \/ ImmunoGen"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"OBT700","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biotherapeutics \/ Genmab","highestDevelopmentStatusID":"5","companyTruncated":"Oxford Biotherapeutics \/ Genmab"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"GORTEC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"MEN1309","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ GORTEC","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ GORTEC"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"OBT620","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"MEN1309","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"BI 764532","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"BI 764532","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"OBT076","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"BI 764532","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"}]

    Find Clinical Drug Pipeline Developments & Deals by Oxford Biotherapeutics

    Menu

    Oxford Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MEN1309

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oxford Doses First Patient with OBT076 in Phase 1b Trial for Head and Neck Cancers

                            Details : OBT076 is a experimental CD205/Ly75-directed ADC which is currently being evaluated in phase 1 clinical trials for the treatment of Adenoid Cystic Carcinoma of the Head and Neck.

                            Brand Name : OBT076

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 18, 2024

                            Lead Product(s) : MEN1309

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BI 764532

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI ...

                            Details : OBT620 (BI 764532) is an investigational DLL3/CD3 IgG-like T-cell engager for potential treatment of patients with advanced or metastatic large-cell neuroendocrine carcinoma of the lung.

                            Brand Name : OBT620

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 29, 2023

                            Lead Product(s) : BI 764532

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BI 764532

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Dosed First Patient in Phase 2 Trial with BI 764...

                            Details : BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein, which is investigated for the treatment of small cell lung cancer and extrapulmonary neuroendocrine cancers.

                            Brand Name : BI 764532

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 24, 2023

                            Lead Product(s) : BI 764532

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BI 764532

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI ...

                            Details : BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein, which is investigated for the treatment of Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers.

                            Brand Name : BI 764532

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 02, 2023

                            Lead Product(s) : BI 764532

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MEN1309,Balstilimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oxford BioTherapeutics Initiates Phase Ib Clinical Trial for OBT076 in Patients with Advanced Solid Tumors by ...

                            Details : OBT076 targets the CD205 receptor on tumor cells as well as certain immune suppressive cells in Combination with CPI Balstilimab for patients with advanced solid tumors.

                            Brand Name : OBT076

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 05, 2023

                            Lead Product(s) : MEN1309,Balstilimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OBT620

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Oxford BioTherapeutics and Boehringer Ingelheim Agree on 2 Year Extension to their Second Multi-Year Collabora...

                            Details : Under the extended agreement, Boehringer is responsible for the development and commercialization of candidates, including OBT620, that interact with the novel targets identified by OBT’s proprietary OGAP® discovery platform for Boehringer’s immuno-...

                            Brand Name : OBT620

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 25, 2023

                            Lead Product(s) : OBT620

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MEN1309

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : GORTEC

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Oxford BioTherapeutics Announces Phase 1b Trial in Collaboration With GORTEC To Investigate OBT076 In Adenoid ...

                            Details : The collaboration aims to investigate OBT076, an ADC utilizing an ImmunoGen toxin in patients with Adenoid Cystic Carcinoma (ACC) of the head and neck. The trial will investigate OBT076 as monotherapy and in sequence with balstilimab.

                            Brand Name : OBT076

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 19, 2023

                            Lead Product(s) : MEN1309

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : GORTEC

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OBT700

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Genmab

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Oxford BioTherapeutics Enters into Commercial License Agreement with Genmab

                            Details : Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics including OBT700R (also known as OBT700), utilizing OBT’s novel, first-in-class IO antibody.

                            Brand Name : OBT700R

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 03, 2022

                            Lead Product(s) : OBT700

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Genmab

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OBT227

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Immunogen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Oxford BioTherapeutics Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugat...

                            Details : The antibodies generated by OBT have been coupled with ImmunoGen's proprietary linker-payload technology, each company will have the opportunity to select one or more development programs including lead OBT0227/OBT227, to further develop on its own.

                            Brand Name : OBT0227

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 13, 2022

                            Lead Product(s) : OBT227

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Immunogen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Oxford Biotherapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MEN1309

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022

                            Details : OBT076 (MEN1309) showed preliminary signs of clinical activity as a monotherapy, with objective responses including long lasting stable disease in six patients, in chemotherapy and checkpoint inhibitor (CPI) refractory patients.

                            Brand Name : OBT076

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 26, 2022

                            Lead Product(s) : MEN1309

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth